Aviva
RIGL icon

Aviva’s Rigel Pharmaceuticals RIGL Stock Holding History

Aviva’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$530K Sell
13,538
-1,634
-11% -$50.4K ﹤0.01% 675
2026
Q1 		$410K Buy
15,172
+3,971
+35% +$133K ﹤0.01% 786
2025
Q4 		$480K Sell
11,201
-2,487
-18% -$93.8K ﹤0.01% 794
2025
Q3 		$388K Sell
13,688
-10,101
-42% -$302K ﹤0.01% 850
2025
Q2 		$446K Buy
23,789
+3,285
+16% +$62.3K ﹤0.01% 828
2025
Q1 		$369K Buy
+20,504
New +$416K ﹤0.01% 830

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aviva's RIGL Position: Q2 2026 in Review

Aviva reduced its Rigel Pharmaceuticals (RIGL) stake by 11% in Q2 2026, selling an estimated $50.4K and leaving 13,538 shares worth $530K. The position accounts for ﹤0.01% of the portfolio, ranked #675.

Aviva first reported a position in RIGL in Q1 2025 and has held it in 6 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Aviva held 13,538 shares of Rigel Pharmaceuticals worth $530K as of Q2 2026.
  • Aviva sold 1,634 Rigel Pharmaceuticals shares in Q2 2026, an estimated $50.4K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #675 holding.
  • Aviva first reported a position in Rigel Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.